ClinicalTrials.gg
RecruitingNCT06106529REDFLASHUpdated Feb 4, 2025

REDucing Hot FLASHes in Women Using Endocrine Therapy.

A Phase 3 interventional study of Oxybutynin and Venlafaxine in Breast Cancer and Hot Flash Due to Medication, sponsored by Reinier de Graaf Groep. Recruiting at 1 site in Netherlands. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Reinier de Graaf Groep · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 390 studies in Breast Neoplasms with a site in Netherlands — 69 open to participants now, 115 under way, 35 of them phase 3. Breast Neoplasms · Netherlands.

Planned enrollment
125th of 314
260 · median 189
Started
2024
with 18 others
Phase 3
105 of 390
10 open now
Primary completion
2029-01
later than 88 of 114 live
Registered
341st of 390
by date

Among the 390 studies in Breast Neoplasms with a site in Netherlands, this one is the 125th largest by planned enrollment of the 314 interventional ones that give a count, is one of 19 that started in 2024, is one of 105 in phase 3, reaches primary completion later than 88 of the 114 other live ones, and was the 341st registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

69 of the 390 studies in Breast Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

64 more — sign in →

All 69 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 390 studies in Breast Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this randomized intrapatient cross-over study is to assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer.

The objectives it aims to answer are:

  • To assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer
  • To assess side effects of oxybutynin versus venlafaxine.
  • To assess the personal preference of women for oxybutynin versus venlafaxine in reducing hot flashes.
  • To assess quality of life of women when reducing hot flashes in women using endocrine therapy after breast cancer.

Participants will fill-out a patient diary during 15 weeks total on a daily basis and receive an (online) questionnaire three times total.

Researchers will compare two groups (venlafaxine group versus oxubutynine group) to assess its efficacy concerning hot flashes.

03

Conditions studied

  • Breast Cancer
  • Hot Flash Due to Medication

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-, peri- or women of 18 years or above;
  • Indication for endocrine therapy and already started with tamoxifen, aromatase inhibitors or luteinizing hormone-releasing hormone analogues for at least 4 weeks and planning to continue for the duration of the study;
  • Experiencing hot flashes with a minimum of 14 per week for at least 1 month and desire to start a pharmacologic intervention.

Exclusion criteria

Exclusion Criteria:

  • Pregnant;
  • Breast feeding;
  • Patients who receive chemotherapy or immunotherapy/ antibodies within the prior 8 weeks, and patients scheduled for chemotherapy during the study period;
  • Palliative setting;
  • Use of venlafaxine or any other antidepressants, also including St. John's wort within the previous year;
  • \< 30 ml/min;
  • Liver cirrhosis;
  • Use of gabapentin and/or calcium channel antagonists within 2 weeks of study entry;
  • Use of oxybutynin before study entry;
  • Use of any other substances or therapies for the treatment of hot flashes, for instance acupuncture.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Venlafaxine

    In this open-label randomized controlled intrapatient cross-over study patients are randomly assigned to one of the two treatment groups. After a one week baseline period, group 1 starts with venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks followed by a two-week wash-out period (no medication), hereafter the group starts with oxybutynin 5 mg twice per day for 6 weeks total.

    Drug: Oxybutynin · Drug: Venlafaxine

  • Experimental
    Oxybutynin

    After a one week baseline period, group 2 starts with oxybutynin 5 mg twice per day for 6 weeks total followed by a two-week wash-out period (no medication), hereafter the group starts with venlafaxine 37.5 mg once daily for 7 days followed by 75mg once daily for 5 weeks.

    Drug: Oxybutynin · Drug: Venlafaxine

Interventions

  • Oxybutynin 5 mg twice per day for 6 weeks

  • Venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks

06

What researchers measure

Primary outcomes

  1. Number and severity of hot flashes

    Number and severity of hot flashes during 6-weeks of therapy measured by the Hot Flash Diary.

    Time frame: 15 weeks total

Secondary outcomes

  1. Quality of life and health status

    Quality of life and health status at baseline and after 6 weeks of treatment measured by the EORTC-QLQ-C30

    Time frame: 15 weeks total

  2. Adverse effects of treatments

    Adverse effects of treatments weekly measured by the National Cancer Institute Common Toxicity Criteria scale, version 5

    Time frame: 15 weeks total

  3. Sleep quality

    Sleep quality at baseline and after 6 weeks of treatment measured by the Groningen Sleep Quality Scale (GSQ)

    Time frame: 15 weeks total

  4. Anxiety and depression

    Anxiety and depression measured at baseline and after 6 weeks of treatment with the Hospital Anxiety and Depression Scale (HADS)

    Time frame: 15 weeks total

  5. Sexual function

    Sexual function measured at baseline and after 6 weeks of treatment with the Sexual Activity Questionnaire (SAQ)

    Time frame: 15 weeks total

  6. Cognitive function

    Cognitive function measured at baseline and after 6 weeks of treatment with the 6-item cognitive impairment test (6-CIT)

    Time frame: 15 weeks total

  7. Adherence

    Ask patients the following question after 6 weeks of treatment: 'Would you like to continue the endocrine therapy for the recommended duration of therapy taking the current medication (oxybutynin or venlafaxine) given the number and severity of hot flashes you experience during the last week?'

    Time frame: 15 weeks total

  8. Preference

    Ask patients the following question after 6 weeks of the final treatment: 'Do you have a preference taking the medication from study period 1 or study period 2?'

    Time frame: 15 weeks total

07

Study locations

1 of 1 sites recruiting
  • Reinier de Graaf Gasthuis
    Delft, Zuid-Holland 2625 AD, Netherlands
    Recruiting
    • Maaike de Leeuw, MSc · ContactM.deLeeuw@rdgg.nl · +31152603035
    • Marte Smits, MSc · Contact
    • Lemonitsa Mammatas, PHD, MSc · Contact
08

References and documents

Individual participant data

Plan to share: Yes — Study protocol, anonymised database and study results may be available on request, after assessment of the reason for request by the study investigators.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jan 2029, 50 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 50 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Oct 30, 2023
StartActual
Oct 3, 2024
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jan 1, 2029
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06106529
Lead sponsor
Reinier de Graaf Groep
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Oct 3, 2024
Primary completion
Jan 1, 2029 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Feb 4, 2025

Study contacts

Marte Smits, MSc
Contact
marte.smits@rdgg.nl
+31152603870
Lemonitsa Mammatas, PhD
principal investigator · Reinier De Graaf Ziekenhuis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxybutynin · Venlafaxine

Start the discussion